Sandostatin and the Belfast experience.
Twenty-four patients with 26 apudomas have been treated with Sandostatin (octreotide) in Belfast. The 2 patients with vipoma showed an excellent response clinically and biochemically. Of 15 patients with carcinoids, Sandostatin improved the diarrhoea in 70%, flush in 58%, and wheeze in 100% of patients. Patients with insulinoma and the Zollinger-Ellison syndrome were unresponsive to Sandostatin. In general, the response to Sandostatin appeared to decline as the tumour size increased and tumour markers rose. Side effects have not been a problem.
Buchanan
K D
KD
Institute of Clinical Science, Queen's University, Belfast, UK.
Collins
J S
JS
Varghese
A
A
Johnston
C F
CF
Shaw
C
C
D001079:Apudoma / Q000188:drug therapy*; D002276:Carcinoid Tumor / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy; D005260:Female; D005483:Flushing / Q000188:drug therapy; D015408:Gastrinoma / Q000188:drug therapy; D006801:Humans; D007340:Insulinoma / Q000188:drug therapy; D009660:Northern Ireland; D015282:Octreotide / Q000627:therapeutic use*; D012135:Respiratory Sounds; D003969:Vipoma / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D015282:Octreotide